Functional Defects of a Muscle-specific Calpain, p94, Caused by Mutations Associated with Limb-Girdle Muscular Dystrophy Type 2A*

Yasuko OnoDagger , Hiroko ShimadaDagger , Hiroyuki SorimachiDagger §, Isabelle Richard, Takaomi C. Saidoparallel , Jacques S. Beckmann, Shoichi IshiuraDagger , and Koichi SuzukiDagger

From the Dagger  Laboratory of Molecular Structure and Functions, Department of Molecular Biology, Institute of Molecular and Cellular Biosciences, University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-0032, Japan,  Généthon, 1, Rue de L'internationale, 91000 Evry, France, and the parallel  Department of Molecular Biology, Tokyo Metropolitan Institute of Medical Science, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-0021, Japan

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

p94 (calpain3), a muscle-specific member of the calpain family, has been shown to be responsible for limb-girdle muscular dystrophy type 2A (LGMD2A), a form of autosomal recessive and progressive neuromuscular disorder. To elucidate the molecular mechanism of LGMD2A, we constructed nine p94 missense point mutants found in LGMD2A and analyzed their p94 unique properties. All mutants completely or almost completely lose the proteolytic activity against a potential substrate, fodrin. However, some of the mutants still possess autolytic activity and/or connectin/titin binding ability, indicating these properties are not necessary for the LGMD2A phenotypes. These results provide strong evidence that LGMD2A results from the loss of proteolysis of substrates by p94, suggesting a novel molecular mechanism leading to muscular dystrophies.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Calpain (EC 3.4.22.17), Ca2+-dependent cysteine protease, is a major intracellular protease thought to regulate the cellular function by hydrolyzing substrates in a highly limited manner (1). Previously identified µ- and m-calpains exist as heterodimers consisting of a unique large catalytic subunit and a common small regulatory subunit. The large subunit can be divided into four structural domains; the second and the fourth domains (domains II and IV) are cysteine protease and Ca2+ binding domains, respectively. The small subunit is composed of an NH2-terminal Gly-rich hydrophobic region (domain V) and a Ca2+ binding domain similar to domain IV of the large subunit (domain IV' or VI).

In addition to these two species, which are ubiquitously expressed in almost all mammalian tissues, several novel species of the calpain large subunit family expressed in a tissue-specific manner have been cloned (2, 3). Thus, it is now established that calpains, at least in mammals, can be classified into two groups, ubiquitous and tissue-specific species, and that the latter should have tissue-specific functions that cannot be accomplished by the former.

p94 (calpain 3 or nCL-1, which stands for novel calpain large subunit) is a muscle-specific member of the calpain large subunit family (2, 4). p94 is expressed predominantly in skeletal muscle where mRNA for p94 is at least 10 times more abundant than those for the µ- and m-calpain large subunits. p94 has three specific insertion sequences, NS, IS1, and IS2. Contributions of these sequences, especially IS2 which includes a nuclear translocation signal, to p94 specific function are presumed.

The recent discovery that the p94 gene is responsible for limb-girdle muscular dystrophy type 2A (LGMD2A)1 supports the idea that p94-specific function is indispensable for normal muscular function (5). LGMD2A is a form of autosomal recessive LGMD, a genetically heterogeneous group of inherited progressive neuromuscular disorders (6, 7). In LGMD2C, -2D, -2E, and -2F, a deficiency in one of the sarcoglycan molecules results in the down-regulation of the whole sarcoglycan complex and the subsequent destabilization of membrane structure (8-13). This is consistent with the fact that deficiencies in structural proteins around the sarcolemma are commonly observed in all muscular dystrophies so far identified except LGMD2A (14).

To investigate the correlation between p94 function and LGMD2A pathology, we tried to evaluate the effects of p94 mutation in LGMD2A focusing on the following p94-specific features, which suggest its pivotal role in protein turnover and/or in function of muscle. First, although p94 is expressed abundantly at the mRNA level in skeletal muscle, little is detectable as protein because of its very rapid autolysis. Moreover, p94 autolyzes even in the presence of excess EGTA, E-64, leupeptin, or calpastatin, a specific proteinaceous inhibitor of conventional calpain (4). This rapid and complete autolysis discriminates p94 from other cysteine proteases including calpains. Second, p94 associates with connectin/titin. Connectin/titin is a gigantic muscle protein in charge of muscle elasticity and structure of myofibrils (15-17). Using the yeast two-hybrid system, we found that p94 binds to the C terminus and the N2A region of connectin/titin (18), suggesting the regulation mechanism of p94 function and myofibril turnover (19).

In this study, we report that all the p94 point mutants found in LGMD2A examined so far completely or almost completely lose the fodrin proteolysis activity and that all the mutants show changes in autolytic activity and/or connectin/titin binding activity. These results indicate that the loss of p94 protease activity rather than its autolytic activity underlies the molecular mechanism of LGMD2A.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Plasmid Construction and Site-directed Mutagenesis-- Wild type human p94 cDNA was constructed into pSRD or pAS2-1 (20-22) for protein expression. Polymerase chain reaction-based mutagenesis using long polymerase chain reaction was employed to create an active site mutation, C129S, and the point mutations found in LGMD2A, L182Q, G234E, P319L, H334Q, V354G, R490W, R572Q, S744G, and R769Q in wild type human p94 cDNA (23). Briefly, sense and antisense primers used to create each amino acid substitution were designed to introduce a diagnostic restriction site at the same time. Each mutant was sequenced to verify the presence of the mutation and the absence of any other alterations. Two clones of human connectin/titin cDNA, pCNT-N2 and pCNT-52, identified as positive for p94 binding in our previous study (18), were subcloned into pACT2 and pGAD10 vectors for binding assay by the yeast two-hybrid system.

Expression in COS7 Cells-- COS7 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum. Transfection was performed by electroporation using a Bio-Rad gene pulser as described previously (24) with 5 µg of each expression vector cDNA or the same amount of pSRD vector and 5 × 106 COS7 cells. For the coexpression experiment, 5 × 106 COS7 cells were transfected by the mixture of expression vector for C129S and that for wild type or mutant p94. The following procedures were carried out within 10 min (from the cell scrape to the addition of SDS) at 0-4° C. 60 h after transfection, the cells were washed three times with phosphate-buffered saline, scraped in phosphate-buffered saline, collected in an ice-cold 1.5-ml tube within 1 min after the scrape of cells. Cells were collected by centrifugation at 4,000 rpm for 2 min, and disrupted by sonication in buffer A (100 mM Tris-HCl, pH 7.5, 10 mM EDTA, 1 mM dithiothreitol). An equal volume of SDS-polyacrylamide gel electrophoresis sample buffer (100 mM Tris-HCl, pH 6.8, 20% (v/v) glycerol, 4% (w/v) SDS, 0.4% (w/v) bromphenol blue, 5% (v/v) 2-mercaptoethanol) was added to the cell extracts immediately after disruption. For the incubation assay, one-third volume of 10 mM EDTA or 50 mM CaCl2 was added to cell extracts prepared as above. Incubation was carried out at 37° C, and the reaction was stopped by adding an equal volume of SDS-polyacrylamide gel electrophoresis sample buffer.

Antipeptide Antisera-- The p94-specific anti-IS2 antiserum was produced using the Lys-rich peptide corresponding to the NH2-terminal Lys-rich sequence of the IS2 region. This antiserum is identical to the anti-K-rich antiserum in our previous report (4). The antibody specific for the proteolyzed 150-kDa form of the fodrin alpha  subunit was raised against the 5-mer peptide, GMMPR, corresponding to the NH2-terminal sequence of the calpain-catalyzed proteolytic fragment (25).

Western Blotting-- Whole cell extracts prepared as described above were fractionated by SDS-polyacrylamide gel electrophoresis in 10 or 6% gels. Sample volumes were normalized according to cell number. Proteins were transferred onto polyvinylidene difluoride membranes (Immobilon P, Millipore, Japan) as recommended by the supplier and incubated with specific antisera as indicated. The secondary antibody was horseradish peroxidase-coupled goat anti-rabbit IgG (Vector Laboratories, Inc., U.S.A.). The antibody complexes were visualized using peroxidase substrate (PODTM immunostaining set, Wako, Japan).

Binding Assay by the Yeast Two-hybrid System-- Wild type and mutant human p94 in pAS2-1, and pCNT-N2 and pCNT-52 human connectin/titin cDNAs in pACT2 and pGAD10 vectors, respectively, were coexpressed in CG-1945 strain Saccharomyces cerevisiae as described by the manufacturer (MATCHMAKERTM Two-Hybrid System, CLONTECH, U.S.A.). Binding was assayed as growth on -Leu,Trp,His plates supplemented with 1.5, 5, or 15 mM 3-amino-1,2,4-triazole and by beta -galactosidase activity using chlorophenol red-beta -D-galactopyranoside as a substrate essentially as described previously (18).

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Connectin/titin Binding Activity of Point Mutants-- As shown in Fig. 1, various point mutations of p94 have been identified in LGMD2A patients (5, 26), and these are expected to abolish one or two but not all of various p94 characteristics described in the Introduction. To clarify which p94 properties is most related to LGMD2A, we constructed 9 of these missense mutations, L182Q, G234E, P319L, H334Q, and V354G in domain II, R490W and R572Q in domain III, and S744G and R769Q in domain IV by site-directed mutagenesis.


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 1.   Schematic structure of human p94. Missense mutations so far identified in LGMD2A are shown. Boxed arrows indicate the nine mutations analyzed in this study. I, II, III, and IV represent the four calpain domains. II is the cysteine protease domain, and IV is the Ca2+ binding domain with four EF-hand motifs represented by hatched boxes. Cys129, His334, and Asn358 represent the active-site residues. NS, IS1, and IS2 indicate three insertion sequences unique to p94.

One question is whether the association with connectin, a unique property of p94, is affected in LGMD2A. Thus, we examined the binding activity of p94 mutants to the clones, pCNT-N2 and pCNT-52 (18), which correspond to the N2A region and the C terminus of human connectin, respectively, using the yeast two-hybrid system.

Wild type and C129S human p94 bound to both pCNT-N2 and pCNT-52, as previously reported (Fig. 2, B and D, 12 and 11). As for the mutants, P319L bound to pCNT-52 but not to pCNT-N2 (Fig. 2, B and D, 4), whereas G234E, R572Q, S744G, and R769Q bound only to pCNT-N2 (Fig. 2, B and D, 3 and 8-10). L182Q and V354G bound to neither pCNT-52 nor pCNT-N2 (Fig. 2, B and D, 2 and 6), but H334Q and R490W associated with both pCNT-N2 and pCNT-52 (Fig. 2, B and D, 5 and 7) as in the case of wild type. These results unexpectedly showed that the inability to bind connectin is not necessarily required for LGMD2A.


View larger version (165K):
[in this window]
[in a new window]
 
Fig. 2.   Connectin/titin binding assay by the yeast two-hybrid system. Wild type and mutant human p94 cDNA in pAS2-1 and connectin clones, pCNT-52 in pGAD10 (A and B), or pCNT-N2 in pACT2 (C and D), were cotransfected into S. cerevisiae CG-1945 strain cells and grown on -(Leu, Trp) plates (A and C), or -(Leu, Trp, His) plates supplemented with 1.5 mM (B), or 5 mM (D) 3-amino-1,2,4-triazole. Combinations are pCNT-52 (A and B) or pCNT-N2 (C and D) and; 1, pAS2-1; 2, L182Q; 3, G234E; 4, P319L; 5, H334Q; 6, V354G; 7, R490W; 8, R572Q; 9, S744G; 10, R769Q; 11, C129S; 12, wild type p94.

Expression of Point Mutants Found in LGMD2A in COS7 Cells-- To examine whether LGMD2A arises from the loss of p94 autolytic activity, we used a COS expression system previously described (4). In this system, wild type p94 is hardly detected as a 94-kDa band because of its rapid autolysis but, instead, as a 55-kDa autolyzed product, whereas an active-site mutated inactive p94, C129S, is clearly detected as a stable 94-kDa translated product (Fig. 3, lanes 2 and 3). Thus, it is concluded that p94 is degraded by itself but not by other endogenous proteases in COS7 cells as we previously reported (4).


View larger version (47K):
[in this window]
[in a new window]
 
Fig. 3.   Expression of wild type and mutant p94 in COS7 cells. Seven mutants lost autolytic activity to various extents. Lysates from COS7 cells transfected with wild type and mutant p94 were analyzed by Western blotting with anti-IS2 antiserum. pSRD (lane 1), wild type human p94 (lane 2), active site mutated C129S (lane 3), L182Q (lane 4), G234E (lane 5), P319L (lane 6), H334Q (lane 7), V354G (lane 8), R490W (lane 9), R572Q (lane 10), S744G (lane 11), R769Q (lane 12), S744G/C129S (lane 13), and R769Q/C129S (lane 14). Closed and open arrowheads indicate the 94-kDa translation product and 55-kDa proteolyzed fragments, respectively.

In the same system, 94-kDa protein products were also observed for the mutants, L182Q, G234E, P319L, H334Q, V354G, R490W, and R572Q (Fig. 3, lanes 4-10). For R572Q, a faint 55-kDa fragment was detected in addition to the clear 94-kDa band, indicating its residual autolytic activity (Fig. 3, lane 10). Thus, these mutants have lost their rapid autolyzing activity as in the case of C129S.

On the other hand, the remaining mutants, S744G and R769Q, were not detected even as degradation fragments (Fig. 3, lanes 11 and 12). To confirm the expression of these two mutants, we introduced a second mutation, C129S, into these constructs. The artificial double mutants, S744G/C129S and R769Q/C129S, expressed the 94-kDa product as much as C129S (Fig. 3, lanes 13 and 14), indicating that both S744G and R769Q disappeared because of autolysis that is possibly even more rapid than wild type p94.

These results showed that the loss of very rapid autolytic activity unique to p94 is not a necessary condition leading to LGMD2A but, at the same time, that none of these mutants possesses the autolytic activity identical to that of wild type p94.

Reduced Autolytic Activity by the Mutations R490W and R572Q-- It looks strange that R572Q mutant, whose mutation localizes in domain III not in the protease domain, showed severely reduced autolytic activity. To clarify the mechanism of the reduction of activity by mutation of domain III, autolysis profiles of R572Q as well as R490W were examined in detail in comparison with wild type and C129S. As our previous studies showed (4), wild type p94 expressed in COS7 cells continues to degrade autocatalytically in the presence of 10 mM EDTA (Fig. 4A). That is, the 55-kDa fragment of wild type p94 disappeared depending on time (Fig. 4A, wild type, lanes 1-4). A similar degradation of the 55-kDa fragment was observed in the presence of Ca2+ (Fig. 4B, wild type, lanes 1-4). These results showed apparent Ca2+-independent autolytic activity of wild type p94. On the other hand, the 94-kDa product of C129S does not undergo remarkable degradation in the presence of EDTA or Ca2+ (Figs. 4, A and B, C129S, lanes 1-4), indicating that endogenous proteases can be ignored in this system.


View larger version (94K):
[in this window]
[in a new window]
 
Fig. 4.   Effects of Ca2+ on the autolysis of R490W and R572Q. Lysates from COS7 cells transfected with pSRD, wild type human p94, R490W, R572Q, and C129S were incubated at 37° C in the presence of 10 mM EDTA (A) or 5 mM Ca2+ (B) for 0, 0.1, 1, and 3 h (lanes 1-4). Closed arrowheads indicate the 94-kDa translation product.

In contrast, R490W and R572Q showed Ca2+-dependent degradation (Figs. 4, A and B). Although the velocity of the degradation is different, the 94-kDa product degraded efficiently to the 55-kDa and/or the smaller fragments only in the presence of Ca2+, but not in the presence of EDTA (Fig. 4, A and B, R490W and R572Q, lanes 1-4). These results suggest that the R490W and R572Q mutations reduce the autolytic activity by lowering their Ca2+ sensitivity. In other words, R490W and R572Q mutations possibly affect interaction between domain II and domain IV, resulting in alteration of the Ca2+ sensitivity and the reduction of the autolytic activity.

Other mutants, L182Q, G234E, P319L, H334Q, and V354G, which lost rapid autolyzing activity (Fig. 3, lanes 4-8), were examined on the alteration of the Ca2+ sensitivity by the same method. The presence of Ca2+ did not compensate for the loss of rapid autolyzing activity for any of these mutants (data not shown).

Enhanced Autolytic Activity by the Mutations in Domain IV, S744G and R769Q-- To further confirm the existence of the proteolytic activity of S744G and R769Q, intermolecular C129S p94 processing activity was examined by coexpression of these mutants with C129S. Wild type p94 has been shown to proteolyze other C129S p94 molecules when coexpressed with C129S in COS7 cells as previously reported (18). When C129S and wild type p94 were coexpressed in COS7 cells and extract of the cells cultured for 60 h were immediately subjected to Western blotting without further incubation, intermolecular cleavage of C129S and production of the 55-kDa proteolyzed fragment were detected by anti-IS2 antiserum (Fig. 5, lane 3).


View larger version (96K):
[in this window]
[in a new window]
 
Fig. 5.   Proteolysis of C129S by p94 mutants. Lysates from COS7 cells transfected with pSRD (lane 1), C129S (lane 2), C129S and wild type human p94 (lane 3), C129S and S744G (lane 4), C129S and R769Q (lane 5), C129S and P319L (lane 6), C129S and R490W (lane 7), and C129S and R572Q (lane 8) were analyzed by Western blotting with anti-IS2 antiserum. Closed and open arrowheads indicate the 94-kDa product of C129S and a 55-kDa proteolyzed fragment, respectively.

In the same manner, when S744G or R769Q was coexpressed with C129S, similar intermolecular cleavage was observed (Fig. 5, lanes 4 and 5), indicating that these two mutants possess protease activity comparable with that of the wild type. Thus, the absence of the autolytic 55-kDa fragment for S744G and R769Q (Fig. 3, lanes 11 and 12) is interpreted as meaning these mutants autolyze more rapidly than wild type p94, with the degradation fragments disappearing almost completely.

Because the NH2 terminus of the 55-kDa fragment was recently determined to be in the IS1 region,2 it is predicted that the mutant P319L in IS1 lost rapid autolytic activity (Fig. 3, lane 6) because of the altered susceptibility of IS1 as a target for autocatalytic cleavage but retains protease activity. Coexpression of C129S with P319L generated the 55-kDa proteolyzed fragment showing intermolecular cleavage of C129S by P319L activity (Fig. 5, lane 6). The mutants, R490W and R572Q, for which residual autolytic activity was demonstrated (Figs. 3 and 4), were also subjected to coexpression with C129S. R490W also has intermolecular C129S processing activity (Fig. 4, lane 7). R572Q generates the 55-kDa fragment when expressed by itself (Fig. 3, lane 10), and thus it was impossible to evaluate its effect on the intermolecular processing activity in this system.

Deficient Proteolysis of the Fodrin alpha  Subunit-- In contrast to our expectations, the nine missense mutants examined showed diverged properties concerning autolytic activity and connectin/titin binding ability as discussed below, although none had properties identical to those of the wild type. This is apparently contradictory to the fact that all nine mutations result in a common phenotype. To seek a property that is altered in all nine mutants, we further analyzed the protease activity of p94 against possible substrates.

It is well established that fodrin is a good substrate for conventional calpains. When calpain digests the fodrin alpha subunit, the 230-kDa full-length molecule is proteolyzed to 150-kDa (27, 28). When wild type p94 is expressed in COS7 cells, the 150-kDa fragment is detected by an antibody to the NH2-terminal sequence of the calpain-catalyzed proteolytic fragment of the fodrin alpha subunit (Fig. 6, lane 2, closed arrowhead), showing significant fodrinolysis in the cytosol (25). In contrast, COS7 cells transfected by C129S or vector only showed no proteolytic fodrin fragment (Fig. 6, lanes 1 and 3). These results clearly indicate that in vivo fodrinolysis is greatly promoted by the expression of wild type p94, if not by p94 itself. In other words, p94 is involved either directly or indirectly in the proteolysis of fodrin by calpain in cultured cells.


View larger version (64K):
[in this window]
[in a new window]
 
Fig. 6.   Proteolysis of fodrin by p94 overexpression. Lysates from COS7 cells transfected with wild type and mutant p94 were analyzed by Western blotting with an antibody specific to the proteolyzed 150-kDa alpha fodrin fragment. pSRD (lane 1), wild type human p94 (lane 2), active site mutated C129S (lane 3), L182Q (lane 4), G234E (lane 5), P319L (lane 6), H334Q (lane 7), V354G (lane 8), R490W (lane 9), R572Q (lane 10), S744G (lane 11), and R769Q (lane 12). The closed arrowhead indicates the 150-kDa fragment.

The expression of other mutant molecules does not generate the 150-kDa proteolyzed fragment of fodrin as efficiently as that of wild type p94 (Fig. 6, lanes 4-12). Surprisingly, cells transfected by S744G or R769Q, which retains autolytic activity and C129S-hydrolyzing activity comparable with wild type (Fig. 3, lanes 11 and 12, Fig. 5, lanes 4 and 5), showed almost undetectable 150-kDa fodrin fragment as shown in Fig. 6, lanes 11 and 12. The result clearly shows that all nine mutants are almost, if not completely, inactive as to fodrinolysis like the active-site mutant, C129S (Fig. 6, lane 3). It is concluded that mutations found in LGMD2A commonly affect the proteolysis by p94.

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

In this study, we examined the properties of p94 point mutants found in LGMD2A (5, 26), and identified a complete or nearly complete loss of in vivo fodrinolysis as a common property of these nine mutants. None of the mutants were identical to wild type p94 as summarized in Table I. Namely, all mutants show a deficiency in autolytic activity and/or binding ability to the N2A and/or C-terminal regions of connectin/titin. Based on the fact that only COS7 cells transfected with wild type human p94 produce substantial amounts of the 150-kDa proteolyzed fodrin fragment, proteolysis of p94 substrates, if not fodrin, is certainly altered in all mutants.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Summary of the properties of nine p94 mutants found in LGMD2A

The involvement of p94 activity in the proteolysis of fodrin observed in our experiments is either direct or indirect. If p94 cleaves fodrin in the same manner as µ- and m-calpains (25), the complete or nearly complete loss of this proteolysis observed for all mutants provides direct evidence that insufficient proteolytic reaction mediated by p94 causes LGMD2A. Alternatively, p94 may regulate fodrinolysis indirectly, i.e. proteolysis of unidentified p94 substrates finally results in the activation of endogenous calpain(s), possibly m-calpain in COS7 cells. In this case, the reduction in the amount of final product, the 150-kDa fragment, can be attributed to a defect in the step catalyzed by p94. Either case is consistent with the idea that a loss of proper protease function is a mechanism for the etiology of LGMD2A, which has been proposed from the existence of mutant species lacking the protease domain.

Our results provide evidence that unique characteristics of p94 distinct from ordinary calpain are functionary important. Our finding that R490W and R572Q can autolyze efficiently only in the presence of Ca2+ emphasizes that p94 is active without Ca2+ or at very low concentrations such as the sub nanomolar level. It is interesting that these mutations in domain III, not IV, altered Ca2+ requirement of p94. Mutagenesis of Asp104 adjacent to the active site Cys105 has been reported to cause a 9-fold increase in the Ca2+ requirement (29). Thus, the Ca2+ requirement of calpain is determined not only by Ca2+ binding domain IV but also by the whole structure including domains I, II, and III.

Autolysis of p94 is rapid and exhaustive but under a certain regulation. The fact that S744G and R769Q autolyze even more rapidly than wild type p94, but cannot catalyze in vivo fodrinolysis as efficiently as wild type p94, means that a too rapid autolysis causes functional defect. This is not unrelated to structural changes in the EF-hands of the Ca2+ binding domain. Recently, the crystal structure of domain IV' (VI) of the calpain small subunit, which is similar to domain IV of the large subunit, has been determined (30, 31). The result shows the existence of five, rather than four EF-hands previously predicted, and reveals that the extreme C-terminal EF-hand structure is involved in the homodimer formation of domain VI. Ser744 and Arg769 corresponding to Ser189 and Arg214 of the small subunit, respectively, are located at the boundary of the alpha -helix and Ca2+ binding loop of EF-3 (Ser744) and EF-4 (Arg769). Thus, it is likely that the S744G or R769Q mutations cause changes in the structure and/or Ca2+ binding affinity of EF-3 and EF-4, resulting in the hyperactivation of p94. We have shown that p94 does not associate with the small subunit under the conditions where the large subunits of µ- and m-calpain show association with the small subunit (18). The above observation suggests that, although p94 shows apparent Ca2+-independent protease activity in vitro, Ca2+ ions play an important role in the regulation of p94 activity, presumably at very low concentrations such as the sub nanomolar level.

Further investigation is required as to how the interaction between p94 and connectin/titin is involved in LGMD2A. We have found no common alteration in connectin/titin binding ability among the nine mutants so far examined. Although the result might indicate that connectin/titin binding has nothing to do with LGMD2A, it does not necessarily exclude physiological importance of an association between p94 and connectin/titin. p94 is known to bind to the Z-line of myofibril other than the N2A and the C-terminal regions, although we have not yet identified the binding site at the molecular level (18). It is therefore, possible that mutant p94 cannot bind to the Z-line. Moreover, because the two p94 binding sites of connectin/titin, N2A and C terminus, are produced by alternative splicing, alternative splicing might regulate the interaction between p94 and connectin/titins (32, 33).

From the viewpoint of molecular mechanism underlying the disease, it is noteworthy that p94, a responsible gene product for LGMD2A, is not a membrane or cytoskeletal component as are the products of the genes responsible for other muscular dystrophies, including LGMD2C-2F. Studies using antisense oligodeoxyribonucleotides showed the involvement of p94 in myofibrillar integrity (34), and thus defects in p94 might cause high susceptibility of the sarcolemma to stress by disturbing proper myogenesis or myodifferentiation. The present work together with the further characterization of p94 function will provide a clear definition and reveal the molecular mechanism of LGMD2A (35-38).

    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ To whom correspondence should be addressed. Tel.: 81-3-3812-2111 (ext. 7821); Fax: 81-3-3813-0654; E-mail: sorimach{at}iam.u-tokyo.ac.jp.

1 The abbreviation used is: LGMD2A, limb-girdle muscular dystrophy type 2A.

2 K. Kinbara, S. Ishiura, S. Tomioka, M. Sorimachi, S. Y. Jeong, S. Amano, H. Kawasaki, B. Kolmerer, S. Kimura, S. Labeit, and K. Suzuki, manuscript in preparation.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Suzuki, K., Sorimachi, H., Yoshizawa, T., Kinbara, K., and Ishiura, S. (1995) Biol. Chem. Hoppe-Seyler 376, 523-529[Medline] [Order article via Infotrieve]
  2. Sorimachi, H., Imajoh-Ohmi, S., Emori, Y., Kawasaki, H., Ohno, S., and Suzuki, K. (1989) J. Biol. Chem. 264, 20106-20111[Abstract/Free Full Text]
  3. Sorimachi, H., Saido, T. C., and Suzuki, K. (1994) FEBS Lett. 343, 1-5[CrossRef][Medline] [Order article via Infotrieve]
  4. Sorimachi, H., Toyama-Sorimachi, N., Saido, T. C., Kawasaki, H., Sugita, H., Miyasaka, M., Arahata, K., Ishiura, S., and Suzuki, K. (1993) J. Biol. Chem. 268, 10593-10605[Abstract/Free Full Text]
  5. Richard, I., Broux, O., Allamand, V., Fougerousse, F., Chiannilkulchai, N., Bourg, N., Brenguier, L., Davaud, C., Pasturaud, P., Roudaut, C., Hillaire, D., Passos-Bueno, M. R., Zatz, M., Tischrield, J. A., Fardeau, M., Jackson, C. E., Cohen, D., and Beckmann, J. S. (1995) Cell 81, 27-40[Medline] [Order article via Infotrieve]
  6. Walton, J. N., and Gardner-Medwin, D. (1988) in The Muscular Dystrophies. In Disorders of Voluntary Muscle (Walton, John, ed), 5th Ed., Churchill Livingstone, Edinburgh, UK
  7. Bushby, K. M. D., and Beckmann, J. S. (1995) Neuromusc. Disord. 5, 337-343[CrossRef][Medline] [Order article via Infotrieve]
  8. McNally, E. M., Yoshida, M., Mizuno, Y., Ozawa, E., and Kunkel, L. M. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 9690-9694[Abstract/Free Full Text]
  9. Roberds, S. L., Letur, F., Allamand, V., Piccolo, F., Jeanpierre, M., Anderson, R. D., Lim, L. E., Lee, J. C., Tomé, F. M. S., Romero, N. B., Fardeau, M., Beckmann, J. S., Kaplan, J. C., and Campbell, K. P. (1994) Cell 78, 625-633[Medline] [Order article via Infotrieve]
  10. Bönnemann, C. G., Modi, R., Noguchi, S., Mizuno, Y., Yoshida, M., Gussoni, E., McNally, E. M., Duggan, D. J., Angelini, C., and Hoffman, E. P. (1995) Nat. Genet. 11, 266-273[Medline] [Order article via Infotrieve]
  11. Lim, L. E., Duclos, F., Broux, O., Bourg, N., Sunada, Y., Allamand, V., Meyer, J., Richard, I., Moomaw, C., Slaughter, C., Tomé, F. M. S., Fardeau, M., Jackson, C. E., Beckmann, J. S., and Campbell, K. P. (1995) Nat. Genet. 11, 257-265[Medline] [Order article via Infotrieve]
  12. Noguchi, S., McNally, E. M., Othmane, K. B., Hagiwara, Y., Mizuno, Y., Yoshida, M., Yamamoto, H., Bönnemann, C. G., Gussoni, E., Denton, P. H., Kyriakides, T., Middleton, L., Hentati, F., Hamida, M. B., Nonaka, I., Vance, J. M., Kunke, L. M., and Ozawa, E. (1995) Science 270, 819-822[Abstract]
  13. Nigro, V., de Sa Moreira, E., Piluso, G., Vainzof, M., Belsito, A., Politano, L., Puca, A. A., Passos-Bueno, M. R., and Zatz, M. (1996) Nat. Genet. 14, 195-198[Medline] [Order article via Infotrieve]
  14. Campbell, K. P. (1995) Cell 80, 675-679[Medline] [Order article via Infotrieve]
  15. Labeit, S., and Kolmerer, B. (1995) Science 270, 293-296[Abstract]
  16. Labeit, S., Kolmerer, B., and Linke, W. A. (1997) Circ. Res. 80, 290-294[Abstract/Free Full Text]
  17. Maruyama, K. (1997) FASEB J. 11, 341-345[Abstract/Free Full Text]
  18. Sorimachi, H., Kinbara, K., Kimura, S., Takahashi, M., Ishiura, S., Sasagawa, S., Sorimachi, N., Shimada, H., Tagawa, K., Maruyama, K., and Suzuki, K. (1995) J. Biol. Chem. 270, 31158-31162[Abstract/Free Full Text]
  19. Sorimachi, H., Kimura, S., Kinbara, K., Kazama, J., Takahashi, M., Yajima, H., Ishiura, S., Sasagawa, N., Nonaka, I., Sugita, H., Maruyama, K., and Suzuki, K. (1996) Adv. Biophys. 33, 101-122[CrossRef][Medline] [Order article via Infotrieve]
  20. Ohno, S., Akita, Y., Konno, Y., Imajoh, S., and Suzuki, K. (1988) Cell 53, 731-741[Medline] [Order article via Infotrieve]
  21. Takebe, M., Seiki, M., Fujisawa, J., Hoy, P., Yokota, K., Arai, K., Yoshida, M., and Arai, N. (1988) Mol. Cell. Biol. 8, 466-472[Medline] [Order article via Infotrieve]
  22. Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K., and Elledge, S. J. (1993) Cell 75, 805-816[Medline] [Order article via Infotrieve]
  23. Braman, J., Papworth, C., and Greener, A. (1996) Methods Mol. Biol. 57, 31-44[Medline] [Order article via Infotrieve]
  24. Chu, G., Hayakawa, H., and Berg, P. (1987) Nucleic Acids Res. 15, 1311-1326[Abstract]
  25. Saido, T. C., Yokota, M., Nagao, S., Yamaura, I., Tani, E., Tsuchiya, T., Suzuki, K., and Kawashima, S. (1993) J. Biol. Chem. 268, 25239-25243[Abstract/Free Full Text]
  26. Fardeau, M., Eymard, B., Mignard, C., Tomé, F. M. S., Richard, I., and Beckmann, J. S. (1996) Neuromusc. Disord. 6, 447-453[CrossRef][Medline] [Order article via Infotrieve]
  27. McMahon, A. P., and Moon, R. T. (1987) Biochem. Soc. Trans. 15, 804-807[Medline] [Order article via Infotrieve]
  28. Harris, A. S., Croall, D. E., and Morrow, J. S. (1988) J. Biol. Chem. 263, 15754-15761[Abstract/Free Full Text]
  29. Arthur, J. S., and Elce, J. S. (1996) Biochem. J. 319, 535-541[Medline] [Order article via Infotrieve]
  30. Blanchard, H., Grochulski, P., Li, Y., Arthur, J. S. C., Davies, P. L., Elce, J. S., and Cygler, M. (1997) Nat. Struct. Biol. 4, 532-538[Medline] [Order article via Infotrieve]
  31. Lin, G., Chattopadhyay, D., Maki, M., Wang, K. K. W., Carson, M., Jin, L., Yuen, P., Takano, E., Hatanaka, M., DeLucas, L. J., and Narayana, S. V. L. (1997) Nat. Struct. Biol. 4, 539-547[Medline] [Order article via Infotrieve]
  32. Kinbara, K., Sorimachi, H., Ishiura, S., and Suzuki, K. (1997) Arch. Biochem. Biophys. 342, 99-107[CrossRef][Medline] [Order article via Infotrieve]
  33. Kolmerer, B., Olivieri, N., Witt, C. C., Herrmann, B. B., and Labeit, S. (1996) J. Mol. Biol. 256, 556-563[CrossRef][Medline] [Order article via Infotrieve]
  34. Poussard, S., Duvert, M., Balcerzak, D., Ramassamy, S., Brustis, J. J., Cottin, P., and Ducastaing, A. (1996) Cell Growth Differ. 7, 1461-1469[Abstract]
  35. van Ommen, G. J. (1995) Nat. Med. 1, 412-414[CrossRef][Medline] [Order article via Infotrieve]
  36. Petrof, B. J., Shrager, J. B., Stedman, H. H., Kelly, A. M., and Sweeney, H. L. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 3710-3714[Abstract]
  37. Bashir, R., Strachan, T., Keers, S., Stephenson, A., Mahjneh, I., Marconi, G., Nashef, L., and Bushby, K. M. (1994) Hum. Mol. Genet. 3, 455-457[Abstract]
  38. Passos-Bueno, M. R., Moreira, E. S., Marie, S. K., Bashir, R., Vasquez, L., Love, D. R., Vainzof, M., Iughetti, P., Oliveira, J. R., Bakker, E., Strachan, T., Bushby, K., and Zatz, M. (1996) J. Med. Genet. 33, 97-102[Abstract]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.